ONE-WAYOngoing theme · still written in the latest filings
Risk of Failure to Maximize the Value of a Specific Pharmaceutical Product Through Additional Indications
The risk that the value of an existing product will not be maximized, or that its revenue plan will not be achieved, due to the approval or development of additional indications, the competitive environment, drug pricing policies, or failure to meet sales targets and milestones.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.
PeriodFY2021 →Still being written about.
Directionhurts0 helps · 1 hurts · 0 flat